$ABTI
ALTEROLA BIOTECH INC. Stock $abti

$abti Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000166357722000679 Filed on November 21, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$540.6K	$448.1K	$138.0K
YoY Change	-80.26%	224.59%	-13.73%
% of Gross Profit
Research & Development		$22.61K	$124.0K
YoY Change		-81.77%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$540.6K	$470.7K	$262.1K
YoY Change	-80.7%	79.59%	63.8%
Operating Profit	$540.6K	-$470.7K	-$262.1K
YoY Change	-119.3%	79.6%
Interest Expense		-$38.00
YoY Change
% of Operating Profit
Other Income/Expense, Net		-$38.00
YoY Change
Pretax Income	-$540.6K	-$470.7K	-$262.1K
YoY Change	-80.7%	79.61%	63.8%
Income Tax	-$5.830K	-$95.47K	$0.00
% Of Pretax Income
Net Earnings	-$534.8K	-$375.3K	-$262.1K
YoY Change	-80.91%	43.18%	63.8%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$0.00	$0.00	-$347.50
COMMON SHARES
Basic Shares Outstanding	807.0M shares	807.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.82K	$15.13K	$175.8K
YoY Change	-68.04%	-91.39%
Cash & Equivalents	$12.82K	$15.13K	$175.8K
Short-Term Investments
Other Short-Term Assets	$142.9K	$131.9K	$13.87K
YoY Change	865.86%	851.12%	-30.65%
Inventory	$967.00	$893.00
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$192.0K	$183.7K	$189.6K
YoY Change	111.68%	-3.1%	848.15%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$12.02M	$12.00M	$34.75K
YoY Change	0.15%	34432.37%
TOTAL ASSETS
Total Short-Term Assets	$192.0K	$183.7K	$189.6K
Total Long-Term Assets	$12.02M	$12.00M	$34.75K
Total Assets	$12.21M	$12.18M	$224.4K
YoY Change	0.99%	5329.96%	1021.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$668.7K	$567.0K	$449.5K
YoY Change	16.35%	26.15%
Accrued Expenses	$12.43K	$362.1K	$545.0K
YoY Change	-97.71%	-33.56%	60.28%
Deferred Revenue
YoY Change
Short-Term Debt	$1.142M	$371.7K	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.823M	$1.301M	$1.084M
YoY Change	49.67%	19.96%	218.94%
LONG-TERM LIABILITIES
Long-Term Debt	$151.3K	$137.6K	$171.9K
YoY Change	-10.52%	-19.92%
Other Long-Term Liabilities	-$30.00	$0.00
YoY Change
Total Long-Term Liabilities	$151.2K	$137.6K	$171.9K
YoY Change	-10.54%	-19.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.823M	$1.301M	$1.084M
Total Long-Term Liabilities	$151.2K	$137.6K	$171.9K
Total Liabilities	$1.974M	$1.438M	$1.256M
YoY Change	42.33%	14.5%	269.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$9.556M	-$9.022M
YoY Change
Common Stock	$807.0K	$807.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.24M	$10.75M	-$1.032M
YoY Change
Total Liabilities & Shareholders Equity	$12.21M	$12.18M	$224.4K
YoY Change	0.99%	5329.96%	1021.9%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$534.8K	-$375.3K	-$262.1K
YoY Change	-80.91%	43.18%	63.8%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$829.6K	-$197.3K	-$108.2K
YoY Change	-66.65%	82.42%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	-$34.75K
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$18.15K
YoY Change	-100.15%
Cash From Investing Activities	$18.15K	$0.00	-$34.75K
YoY Change	-100.15%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	796.5K	295.9K	320.4K
YoY Change	-94.43%	-7.65%
NET CHANGE
Cash From Operating Activities	-829.6K	-197.3K	-108.2K
Cash From Investing Activities	18.15K	0.000	-34.75K
Cash From Financing Activities	796.5K	295.9K	320.4K
Net Change In Cash	-14.97K	98.56K	177.5K
YoY Change	-89.9%	-44.46%
FREE CASH FLOW
Cash From Operating Activities	-$829.6K	-$197.3K	-$108.2K
Capital Expenditures		$0.00	-$34.75K
Free Cash Flow		-$197.3K	-$73.40K
YoY Change		168.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001442999
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2022Q3	us-gaap	Funds Held Under Reinsurance Agreements Asset FundsHeldUnderReinsuranceAgreementsAsset		usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent		usd
CY2022Q1	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable		usd
CY2022Q3	us-gaap	Revenues Revenues		usd
CY2021Q3	us-gaap	Revenues Revenues		usd
	us-gaap	Revenues Revenues		usd
	us-gaap	Revenues Revenues		usd
CY2021Q3	us-gaap	Professional Fees ProfessionalFees		usd
	us-gaap	Professional Fees ProfessionalFees		usd
CY2021Q3	us-gaap	Salaries And Wages SalariesAndWages		usd
	us-gaap	Salaries And Wages SalariesAndWages		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-262078	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	136721	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Interest Expense InterestExpense		usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2021Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount		usd
	ABTI	Stock Subscription Delivered StockSubscriptionDelivered		usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
	ABTI	Increase In Funds In Attorney Trust Account IncreaseInFundsInAttorneyTrustAccount		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities		usd
	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1		usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware		usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
	us-gaap	Interest Paid InterestPaid		usd
	us-gaap	Interest Paid InterestPaid		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	333-156091
	dei	Entity Registrant Name EntityRegistrantName	Alterola Biotech, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1317032
	dei	Entity Address Address Line1 EntityAddressAddressLine1	47 Hamilton Square
	dei	Entity Address City Or Town EntityAddressCityOrTown	Birkenhead Merseyside
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	CH41 5AR
	dei	Entity Address Country EntityAddressCountry	GB
	dei	City Area Code CityAreaCode	151
	dei	Local Phone Number LocalPhoneNumber	601 9477
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	807047948	shares
CY2022Q3	us-gaap	Cash Cash	15130	usd
CY2022Q1	us-gaap	Cash Cash	63816	usd
CY2022Q1	us-gaap	Funds Held Under Reinsurance Agreements Asset FundsHeldUnderReinsuranceAgreementsAsset	12409	usd
CY2022Q3	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	35804	usd
CY2022Q1	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	50686	usd
CY2022Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	131917	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	893	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	1050	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	183744	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	264681	usd
CY2022Q3	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	12000000	usd
CY2022Q1	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	12000000	usd
CY2022Q3	us-gaap	Assets Assets	12183744	usd
CY2022Q1	us-gaap	Assets Assets	12264681	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	567043	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	542510	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	362086	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	396486	usd
CY2022Q3	us-gaap	Loans Payable Current LoansPayableCurrent	75000	usd
CY2022Q3	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	296730	usd
CY2022Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	98470	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1300859	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1037465	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	137627	usd
CY2022Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	164220	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	137627	usd
CY2022Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	164220	usd
CY2022Q3	us-gaap	Liabilities Liabilities	1438486	usd
CY2022Q1	us-gaap	Liabilities Liabilities	1201685	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	807047948	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	807047948	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	802633333	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	802633333	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	807048	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	802633	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18927919	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17942833	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9021731	usd
CY2022Q3	us-gaap	Legal Fees LegalFees	5418	usd
CY2021Q3	us-gaap	Legal Fees LegalFees	10295	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7833790	usd
CY2022Q1	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	136721	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	32021	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	14599	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	10745258	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	11062996	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12183744	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12264681	usd
CY2022Q3	ABTI	Accounting And Audit Fees AccountingAndAuditFees	32898	usd
CY2021Q3	ABTI	Accounting And Audit Fees AccountingAndAuditFees	20743	usd
	ABTI	Accounting And Audit Fees AccountingAndAuditFees	67815	usd
	ABTI	Accounting And Audit Fees AccountingAndAuditFees	29135	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	111614	usd
	us-gaap	Professional Fees ProfessionalFees	114010	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22614	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	124034	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41086	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	260325	usd
	us-gaap	Legal Fees LegalFees	8029	usd
	us-gaap	Legal Fees LegalFees	11014	usd
CY2022Q3	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	21852	usd
CY2021Q3	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	13874	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	518640	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	13874	usd
CY2022Q3	ABTI	Consulting Fees ConsultingFees	155674	usd
CY2021Q3	ABTI	Consulting Fees ConsultingFees	93650	usd
	ABTI	Consulting Fees ConsultingFees	283094	usd
	ABTI	Consulting Fees ConsultingFees	93650	usd
CY2022Q3	us-gaap	Salaries And Wages SalariesAndWages	96448	usd
	us-gaap	Salaries And Wages SalariesAndWages	193876	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24163	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	-518	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	56821	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4640	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	470682	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	262078	usd
	us-gaap	Operating Expenses OperatingExpenses	1283371	usd
	us-gaap	Operating Expenses OperatingExpenses	412638	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-470682	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-262078	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1283371	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-412638	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	-38	usd
	us-gaap	Interest Expense InterestExpense	-38	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-38	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-38	usd
CY2022Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	95469	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	95469	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-375252	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1187941	usd
	us-gaap	Net Income Loss NetIncomeLoss	-412638	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022Q3	ABTI	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	807047948	shares
CY2021Q3	ABTI	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	754280000	shares
	ABTI	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	806332740	shares
	ABTI	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	754280000	shares
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	136	usd
	ABTI	Related Party Interest Forgiven RelatedPartyInterestForgiven	1544	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-403743	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-14023	usd
	us-gaap	Net Income Loss NetIncomeLoss	-343033	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-759119	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28622	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	136721	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	231936	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	12000000	usd
	ABTI	Stock Issued During Period Value S1 Registration StockIssuedDuringPeriodValueS1Registration	2399250	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3360000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6334414	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	11062996	usd
CY2022Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	175074	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	50000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	280	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	321000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	481500	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-812689	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	11278161	usd
CY2022Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-157651	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-375252	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	10745258	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1187941	usd
	us-gaap	Net Income Loss NetIncomeLoss	-412638	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	802500	usd
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-131917	usd
	ABTI	Stock Subscription Delivered StockSubscriptionDelivered	136721	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1099	usd
	ABTI	Increase In Funds In Attorney Trust Account IncreaseInFundsInAttorneyTrustAccount	12409	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14882	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	24533	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	342501	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-34400	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	195194	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-232832	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-363213	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-108874	usd
	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	-34746	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-34476	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	-246667	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	-11608	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	50280	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	137627	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	171863	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	296947	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	321098	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	17579	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	-2240	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-48686	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	175238	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63816	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	519	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15130	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	175757	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	802500	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	136721	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_808_eus-gaap--NatureOfOperations_ztNNK7BPSRO4" style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – NATURE OF BUSINESS</b></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After formation, the Company was in the business of mineral exploration. On May 3, 2010, the Company sold its mineral exploration business and entered into an Intellectual Property Assignment Agreement (“IP Agreement”) with Soren Nielsen pursuant to which Mr. Nielsen transferred his right, title and interest in all intellectual property relating to certain chewing gum compositions having appetite suppressant activity (the “IP”) to the Company for the issuance of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20100402__20100503__us-gaap--StatementEquityComponentsAxis__custom--IssuanceOneMember_pdd">55,000,000</span> shares of the Company’s common stock.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the acquisition of the IP the Company changed its business direction to pursue the development of chewing gums for the delivery of Nutraceutical/functional ingredients for applications such as appetite suppressant, cholesterol suppressant, vitamin delivery, antioxidant delivery and motion sickness suppressant.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 19, 2021, the Company entered into an Stock Purchase Agreement (the “Agreement”) with ABTI Pharma Limited, a company registered in England and Wales (“ABTI Pharma”), pursuant to which the Company agreed to acquire all of the outstanding shares of capital stock of ABTI Pharma from its shareholders in exchange for <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210101__20210129__us-gaap--StatementEquityComponentsAxis__custom--IssuanceTwoMember_pdd">600,000,000</span> shares of the Company pro rata to the ABTI Pharma shareholders. The shares were issued on January 29, 2021 in anticipation of the closing and the parties to the transaction agreed in a March 24, 2021 amendment to close upon the ABTI Pharma Limited Shares being transferred to the Company, which was to occur upon the filing by the Company of its outstanding December 31, 2020 quarterly report on Form 10-Q, which was filed on May 28, 2021 with the Securities and Exchange Commission. The transaction closed on May 28, 2021.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The business plan of the company will no longer be focused on a chewing gum delivery system but it will re-focus its activities to the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs), pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs and European novel food approval of cannabinoid-based, cannabinoid-like and non-cannabinoid ingredients and products .In addition, the company plans to develop such bulk ingredients for supply into the cosmetic sector.</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transaction is being accounted for as a reverse acquisition and recapitalization. ABTI Pharma is the acquirer for accounting purposes and the Company is the issuer. The historical financial statements presented are the financial statements of Alterola Biotech Inc.. The Agreement was treated as a recapitalization and not as a business combination; at the date of the acquisition, the net liabilities of the legal acquirer, Alterola, were less than <span id="xdx_90B_ecustom--NetLiabilitiesOfAcquirerReverseAcquisition_iI_c20210119_zStpxap1dxcb">$50,000</span>.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q1	ABTI	Net Liabilities Of Acquirer Reverse Acquisition NetLiabilitiesOfAcquirerReverseAcquisition	50000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zVbQzdguQec9" style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Use of Estimates</span></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	807047948	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	807047948	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	761780000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	761780000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	12000000	usd
CY2022Q3	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	12000000	usd
CY2022Q3	us-gaap	Loans Held For Sale Term LoansHeldForSaleTerm	P90D
CY2022Q3	us-gaap	Loans Payable Current LoansPayableCurrent	75000	usd
CY2022Q3	ABTI	Shares Committed For Loan Payable SharesCommittedForLoanPayable	2250000	shares
CY2022Q3	us-gaap	Capital Capital	1117115	usd
	us-gaap	Profit Loss ProfitLoss	-9021731	usd

Files In Submission

Name	View Source	Status
0001663577-22-000679-index-headers.html	Edgar Link	pending
0001663577-22-000679-index.html	Edgar Link	pending
0001663577-22-000679.txt	Edgar Link	pending
0001663577-22-000679-xbrl.zip	Edgar Link	pending
abti-20220930.xsd	Edgar Link	pending
abti10q.htm	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
abti-20220930_cal.xml	Edgar Link	unprocessable
abti-20220930_def.xml	Edgar Link	unprocessable
abti-20220930_lab.xml	Edgar Link	unprocessable
abti-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
abti10q_htm.xml	Edgar Link	completed
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABTI
ALTEROLA BIOTECH INC. Stock $abti

2022 Q4 Form 10-Q Financial Statement

#000166357722000679 Filed on November 21, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABTI ALTEROLA BIOTECH INC. Stock $abti

2022 Q4 Form 10-Q Financial Statement

#000166357722000679 Filed on November 21, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABTI
ALTEROLA BIOTECH INC. Stock $abti